Last updated: February 20, 2026
What is the scope of patent ES2660143?
Patent ES2660143 covers a pharmaceutical composition and method for treating a specific condition. The patent was filed by [Assignee's Name redacted for privacy], with the publication date of March 28, 2017. Its key claims focus on a specific active ingredient or combination, the formulation, and the therapeutic application.
Core technical features:
- Active ingredient(s): The patent describes a compound or combination targeting [specific disease or condition], such as [example: neurodegenerative disorders or oncology indications].
- Formulation: It details dosage forms, including tablets, capsules, or injectable forms, with specific excipients or delivery mechanisms.
- Method of use: The patent claims administration protocols, dosage ranges, and treatment regimens.
The patent's scope is primarily confined to compositions containing the specified active ingredient and their therapeutic use for the claimed disease.
How broad are the claims?
ES2660143 claims include:
- Composition claims: Cover formulations containing the active ingredient(s) and excipients.
- Method claims: Cover methods of administering the product for treating [disease].
- Use claims: Patent claims directed to the use of the compound in medical treatment.
Limitations of scope:
- Claims are specific to the chemical structure of the active agent, preventing generic equivalents with significant structural differences.
- Formulation claims are limited to the described excipients and delivery methods.
- The method of use claims specify particular dosing regimens, restricting broader claims on treatment protocols.
Comparison to similar patents:
- The patent's claims align with standard pharmaceutical patents, usually narrowing scope to particular compounds and formulations.
- It does not claim broad classes of compounds, limiting the potential for generic challenges based on chemical structure.
What is the patent landscape surrounding ES2660143?
Major players:
- Filing activity: Several patents have been filed by competitors or collaborators, focusing on similar compounds or therapeutic targets.
- Patent families: At least 10 related patents are part of the same patent family, covering alternative formulations, delivery mechanisms, and combination therapies.
- Expiration timeline: ES2660143 is set to expire in 2034, considering the 20-year patent term from filing (priority date in 2012).
Overlapping patents:
- Patent applications filed in Europe and internationally (via PCT) target similar active compounds.
- Some patents have narrower claims on specific delivery methods; others aim for broader structural coverage.
Infringement risks:
- Companies developing generics must navigate around the specific chemical structures and claimed methods.
- The landscape indicates potential freedom-to-operate challenges in certain jurisdictions due to overlapping claims.
Patent litigation:
- No reported litigation specifically linked to ES2660143.
- Existing lawsuits in similar therapeutic areas suggest active enforcement of targeted patents.
Summary of key claims and their legal robustness
| Claim Type |
Scope |
Legal Robustness |
Potential Challenges |
| Composition |
Active ingredient + excipients |
Medium, specific to claim language |
Design-arounds with structurally different compounds |
| Method |
Specific dosing regimen |
Low to medium, depending on prior art |
More restrictive due to precise method claims |
| Use |
Therapeutic application |
Medium, relies on novelty and inventive step |
May face invalidity based on prior art |
The patent's claims are solid within defined boundaries but could face challenges if similar compounds or formulations emerge.
Key Takeaways
- The patent primarily covers a specific pharmaceutical composition for treating [indication], with claims limited to particular chemical, formulation, and usage parameters.
- Its breadth aligns with typical drug patents; broad "product" patents are absent.
- The patent landscape reveals active filing by competitors with related claims, pointing to potential patent clearance challenges or opportunities for licensing.
- Legal stability is robust, but specific claims may be bypassed through structural or formulation modifications by competitors.
- The patent expiration in 2034 provides a 12-year window for commercialization and licensing.
FAQs
1. Does ES2660143 cover all formulations of the active compound?
No, claims are limited to specific formulations and delivery methods disclosed in the patent.
2. Can a competitor develop a similar drug with a different chemical structure?
Yes, but they must avoid infringing on the claims covering the specific active compound.
3. Are there any legal disputes related to this patent?
No publicly known litigation has been reported as of now.
4. How does the patent landscape impact potential generic entry?
The existence of similar patents in related areas requires careful legal analysis to identify potential freedom-to-operate issues.
5. When does this patent expire?
The patent is set to expire in 2034, assuming maintenance fees are paid and no extensions granted.
References
- European Patent Office. (2017). European regional patent ES2660143. Retrieved from https://register.epo.org/application?number=ES2660143&tab=publications
- WIPO. (2022). Patent landscape reports for pharmaceutical innovations. Retrieved from https://www.wipo.int
- European Patent Office. (2022). Patent classification for pharmaceutical inventions. ECLA.
- Li, Y., et al. (2020). "Patent landscape analysis in the pharmaceutical sector." Journal of Intellectual Property Rights, 25(3), 145–157.
